Ratings Surperformance

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA

Ratings ESG MSCI

Ratings Myriad Genetics, Inc.: Strengths and Weaknesses

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Highlights: Myriad Genetics, Inc.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • Historically, the company has been releasing figures that are above expectations.
Weaknesses: Myriad Genetics, Inc.
  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
  • Over the past twelve months, analysts' opinions have been revised negatively.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Rating Financials

Myriad Genetics, Inc. SectorUnited States
Fundamentals -
Growth
Revenue growth
EPS growth
FCF growth
Profitability
EBITDA Margin
EBIT Margin
Net Margin
Capital Efficiency-
ROA-
ROCE-
ROE
Financial Health-
Gearing-
Leverage
Capital Intensity
Balance sheet growth-
Long Term balance sheet growth-
Long term revenue growth
Long term EPS growth-
More ratings

Rating Valuation

Myriad Genetics, Inc. SectorUnited States
Global Valuation -
Enterprise value
EV/Revenue
EV/EBITDA
EV/FCF-
Equity Valuation-
P/E-
PBR
Dividend Yield-
EV/EBIT
CAPEX/Revenue
More ratings

Rating Consensus

Myriad Genetics, Inc. SectorUnited States
Consensus
Analysts' buy/sell recommendations
Analysts' recommendations evolution (1 year)
Analysts' recommendations evolution (4 months)
Analysts' target price
Analysts' target price evolution (1 year)
Analysts' target price evolution (4 months)
Analysts' recommendations evolution (7 days)
Target Price evolution (7 days)
More ratings

Rating Business Predictability

Myriad Genetics, Inc. SectorUnited States
Visibility
Analysts' coverage
Financial estimates divergence
Analysts' recommendations divergence
Analysts' Target price divergence
Surprise rates

Rating Revisions

Myriad Genetics, Inc. SectorUnited States
Financial revisions
Revenue revisions (1 year)
Revenue revisions (4 months)
EPS revisions (1 year)
EPS revisions (4 months)
EPS revisions (7 days)
Revenue revisions (7 days)
More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
661M -
AA
- -
14.39B
A
13.14B -
AA
- -
8.14B - - - - -
6.65B
BBB
4.2B
BBB
-
3.91B
BBB
2.92B
CCC
-
2.43B - - - - - - -
2.25B -
BBB
- -
Average 5.87B
A
Weighted average by Cap.
A
See all sector ratings
  1. Stock Market
  2. Equities
  3. MYGN Stock
  4. Ratings Myriad Genetics, Inc.